Sarah Cannon Research Institute shared a post on LinkedIn:
“New data from the phase 3 frontMIND trial, presented at the ASCO 2026 Annual Meeting, suggest that adding tafasitamab and lenalidomide to R-CHOP may improve outcomes for patients with high-risk DLBCL, demonstrating a 25% improvement in progression-free survival vs R-CHOP alone.
In an interview with AJMC – The American Journal of Managed Care , Dr. John Burke of SCRI at Rocky Mountain Cancer Centers, shared clinical perspective on the regimen’s rationale, its manageable safety profile, and its feasibility in community oncology settings.
Read the American Journal of Managed Care article and learn more: frontMIND: Results With Tafasitamab Improve PFS 25% Over R-CHOP for High-Risk DLBCL.”
Other articles about Sarah Cannon Research Institute on OncoDaily.